60 Degrees Pharmaceuticals Inc. (SXTP)
NASDAQ (CM) NASDAQ (CM) Primary 
60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should Know
60 Degrees Pharmaceuticals Inc. (SXTP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What's Going On With 60 Degrees Pharmaceuticals On Friday?
60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) shares are down during Friday's premarket session. This follows a 9.6% decline, closing at $2.91 on Thursday.
Here's Why 60 Degrees Pharmaceuticals Inc. (SXTP) Looks Ripe for Bottom Fishing
60 Degrees Pharmaceuticals Inc. (SXTP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q3 Loss, Misses Revenue Estimates
60 Degrees Pharmaceuticals Inc. (SXTP) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $3.60 per share a year ago.
60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q2 Loss, Tops Revenue Estimates
60 Degrees Pharmaceuticals Inc. (SXTP) came out with a quarterly loss of $4.23 per share versus the Zacks Consensus Estimate of a loss of $3.96. This compares to loss of $16.81 per share a year ago.
Why Is 60 Degrees Pharmaceuticals (SXTP) Stock Up 29% Today?
60 Degrees Pharmaceuticals (NASDAQ: SXTP ) stock is gaining on Monday after the specialty pharmaceutical company announced an agreement with the University of Kentucky. This agreement will have the University of Kentucky conducting a Phase IIb clinical trial of SJ733.
Why Is 60 Degrees (SXTP) Stock Up 56% Today?
60 Degrees (NASDAQ: SXTP ) stock is on the rise Friday alongside heavy early morning trading of the specialty pharmaceutical company's shares. This has more than 12.5 million shares of SXTP stock being traded as of this writing.
60 Degrees Pharmaceuticals, Inc. to Post Q2 2024 Earnings of ($0.33) Per Share, HC Wainwright Forecasts (NASDAQ:SXTP)
60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP – Free Report) – HC Wainwright lowered their Q2 2024 earnings per share (EPS) estimates for 60 Degrees Pharmaceuticals in a research report issued on Thursday, May 16th. HC Wainwright analyst E. White now expects that the company will post earnings per share of ($0.33) for the quarter, down from their prior forecast of ($0.07). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for 60 Degrees Pharmaceuticals’ current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for 60 Degrees Pharmaceuticals’ Q3 2024 earnings at ($0.12) EPS, Q4 2024 earnings at ($0.12) EPS, FY2024 earnings at ($0.56) EPS, FY2025 earnings at ($0.11) EPS and FY2026 earnings at ($0.04) EPS. 60 Degrees Pharmaceuticals Trading Up 0.9 % Shares of NASDAQ SXTP opened at $0.22 on Monday. The firm has a market cap of $2.76 million and a P/E ratio of -0.22. 60 Degrees Pharmaceuticals has a 1-year low of $0.20 and a 1-year high of $8.65. The business’s 50 day moving average is $0.25 and its 200-day moving average is $0.49. 60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) last announced its earnings results on Monday, April 1st. The company reported ($0.44) earnings per share for the quarter. The firm had revenue of ($0.10) million during the quarter, compared to the consensus estimate of $0.06 million. About 60 Degrees Pharmaceuticals (Get Free Report) 60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. Read More Five stocks we like better than 60 Degrees Pharmaceuticals Dividend Capture Strategy: What You Need to Know MarketBeat Week in Review – 5/13 – 5/17 Buy P&G Now, Before It Sets A New All-Time High Take-Two Interactive Software Offers 2nd Chance for Investors What Investors Must Know About Over-the-Counter (OTC) Stocks Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
